Overview

* Werewolf Therapeutics ( HOWL ) Q3 net loss narrows slightly from last year

* Research and development expenses decreased in Q3 compared to same period in 2024

* Company received Fast Track Designation for WTX-124 from the US FDA

Outlook

* Werewolf to update on WTX-124 Phase 1/1b trial in Q4 2025

* Company plans WTX-330 trial update in Q4 2025

* Werewolf to nominate WTX-1011 target by year-end 2025

Result Drivers

* Research and development expenses were $11.6 million for the third quarter of 2025, compared to $12.5 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$16.37

Income mln

Q3 Basic -$0.36

EPS

Q3 $15.72

Operatin mln

g

Expenses

Q3 -$15.72

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Werewolf Therapeutics Inc ( HOWL ) is $7.00, about 81.3% above its November 3 closing price of $1.31

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)